<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article146</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/COAPT" style="display:block; margin-bottom:10px;">COAPT Original</a></li>
<h2><strong>COAPT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Transcatheter Mitral-Valve Repair in Heart Failure Patients with Mitral Regurgitation".The New England Journal of Medicine. 2018. DOI: 10.1056/NEJMoa1806640.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does transcatheter mitral-valve repair improve clinical outcomes in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remain symptomatic despite maximal doses of guideline-directed medical therapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Transcatheter mitral-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and all-cause mortality within 24 months in patients with heart failure and significant secondary mitral regurgitation.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Patients with heart failure and secondary mitral regurgitation who remain symptomatic despite medical therapy have few treatment options and a poor prognosis. Transcatheter mitral-valve repair may reduce heart failure symptoms and potentially improve survival for these patients.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No guidelines were specified within the study. The treatment modalities were chosen according to standard medical guidelines for heart failure therapy.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, controlled, parallel-group, open-label trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Enrolled 614 patients at 78 centers in the United States and Canada with heart failure and secondary mitral regurgitation.<br/>
<br/>
Inclusion Criteria<br/>
- Left ventricular ejection fraction of 20 to 50%<br/>
- Moderate-to-severe or severe secondary mitral regurgitation<br/>
- Symptomatic (NYHA class II, III, or IVa) despite maximal doses of guideline-directed medical therapy<br/>
<br/>
Exclusion Criteria<br/>
The specific exclusion criteria were not disclosed in the summary.<br/>
<br/>
Baseline Characteristics<br/>
- Mean age: 72.2 ± 11.2 years<br/>
- 36.0% women<br/>
- 36.5% received cardiac resynchronization therapy<br/>
- Mitral regurgitation grade 3+ in 52.2% and 4+ in 47.8%<br/>
- Mean STS score: 8.2 ± 5.9%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to receive either transcatheter mitral-valve repair plus medical therapy (device group) or medical therapy alone (control group).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Effectiveness<br/>
- Hospitalizations for heart failure within 24 months<br/>
<br/>
Primary Safety<br/>
- Freedom from device-related complications at 12 months<br/>
<br/>
Secondary Outcomes<br/>
- All-cause mortality within 24 months<br/>
- Quality of life and functional capacity within 24 months<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
The trial was open-label, with potential for bias in intervention awareness. Longer median follow-up in the device group, possibly due to lower mortality. By chance, a higher use of agents affecting the renin–angiotensin axis was noted in the device group at baseline.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by Abbott.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Full text available at nejm.org and ClinicalTrials.gov number, NCT01626079.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
